Research Area: Cancer
Biological Activity:
Ketanserin (Vulketan Gel) is specific 5-HT2A serotonin receptor antagonist with a Ki of 2.5 nM for rat and human 5-HT2A. Ketanserin (Vulketan Gel) is a drug with affinity for multiple G protein-coupled receptors. Ketanserin ( Vulketan Gel) inhibits rat and human 5-HT2C with Ki of 50 and100 nM, respectively and has higher affinity binding for alpha-1 adrenergic (Ki = ~ 40 nM) and Histamine H1 (Ki = 2 nM). Ketanserin (Vulketan Gel) can also be used to discriminate between 5-HT1D and 5-HT1B receptor subtypes. Ketanserin (Vulketan Gel) has antihypertensive properties. Ketanserin (Vulketan Gel) also reduces platelet aggregation produced by serotonin. Ketanserin also has high affinity for alpha-1 adrenergic receptors, and very high affinity for histamine H1 receptors. Ketanserin (Vulketan Gel) was shown to reduce the severity and frequency of the vasospasm in Raynaud’s phenomenon. [1][2][3]References on Ketanserin (Vulketan Gel)[1] http://en.wikipedia.org/wiki/Ketanserin, , [2] Neurochem Int., 1995 Dec, 27(6):489-96.[3] Eur J Pharmacol., 1991 Jan 25, 206(1):39-45.